Dr. Karen L. Kelly, MD
- Medicare services, 2022
- 13
- Part D claims, 2022
- 150
- Publications
- 54
- Clinical trials
- 13
- Hospital affiliations
- 1
- Practice address
- 2315 Stockton Boulevard, Sacramento, CA 95817
- Practice phone
- Call (916) 734-2011
- Professional email
- Get professional email
- Personal email
- Get personal email
- Mobile number
- Get mobile number
Primary practice
Find Dr. Kelly's professional email, personal email and mobile number
Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.
Dr. Karen L. Kelly is a hematologist and oncologist in Sacramento, California
Dr. Kelly practices at UC Davis Medical Center in Sacramento, California, part of University of California Health.
Dr. Kelly's NPI, 1477651222, was assigned on September 20, 2006. Dr. Kelly graduated from University of Kansas School of Medicine - Kansas City in 1984. Dr. Kelly's California license number on file is G88845.
- NPI
- 1477651222NPI Registry (opens in a new tab)
- NPI enumeration date
- September 20, 2006
- NPI status
- Active
- Practice phone
- (916) 734-2011
- Professional email
- Get email
- Personal email
- Get email
- Mobile number
- Get number
- Sex
- Female
- Estimated age
- 68
- Medical school graduation
- 1984
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Affiliation Data
Dr. Karen L. Kelly practices at UC Davis Medical Center in Sacramento, California
Dr. Kelly's primary practice is UC Davis Medical Center, at 2315 Stockton Boulevard, Sacramento, CA 95817 in Sacramento County. The practice phone is (916) 734-2011.
- UC Davis Medical Center2315 Stockton Boulevard, Sacramento, CA 95817 · Sacramento CountyPhone(916) 734-2011
Source: Dmand AI Affiliation Data
Dr. Karen L. Kelly is affiliated with 2 sites of care and 1 medical group
Dr. Kelly's primary practice is UC Davis Medical Center in Sacramento, California, part of University of California Health. The medical group on file is UC Davis Medical Group. Dmand AI also links Dr. Kelly to 1 more group practice or clinic, named with a free account.
Sources: Dmand AI Affiliation Data; and Dmand AI Org Hierarchy Data
Dmand AI tracks the EHR system at Dr. Karen L. Kelly's practice
Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kelly practices, 2 sites in all. Vendor and product names are available with a free account.
| Site | EHR vendor and product |
|---|---|
| UC Davis Medical Center | Available with a free account |
| +1 more affiliated site | Available with a free account |
Source: Dmand AI Technology Install Data
For health IT teams
Dmand AI maps EHR vendors, IT decision makers and buying committees across University of California Health and 6.2K+ hospitals, with verified contacts in the same login.
Dr. Karen L. Kelly is one of 1,502 hematologists and oncologists in California
Hematology and oncology is Dr. Kelly's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Kelly is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Kelly's licenses on file in 4 states: California, Kansas, Colorado and New Mexico.
Specialties and state licenses
- Hematology and oncology, CaliforniaPrimary
- Kansas license
- Medical oncology, Colorado
- New Mexico license
Hematologists and oncologists near Dr. Kelly
Counts of hematologists and oncologists with a Dmand AI profile, by place and practice. Each opens the list.
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks
Dr. Karen L. Kelly billed Medicare for 13 services in 2022
CMS data shows 13 Medicare services from Dr. Kelly across 1 procedure code in 2022, all of them office visits. Medicare paid $1,130 for them. Every service was in a facility, such as a hospital, rather than an office.
Dr. Kelly's Medicare services by type, 2021 to 2022
- 2021
- 2022
- Office and hospital visits
- 2021: 3942022: 1397%
Dr. Kelly compared with the California median for hematologists and oncologists, 2022
- Dr. Kelly
- California median
- Medicare services
- 13vs 93299% below
- Part D claims
- 150vs 39462% below
Medians across 1,367 hematologists and oncologists in California with Dmand AI profiles that report each measure.
Dr. Kelly's most billed Medicare procedure codes, 2022
CMS publishes codes billed for 11 or more Medicare patients. Each label is the code family; CPT descriptions are licensed by the AMA.
Need commercial claims for Dr. Kelly?
Medicare shows one payer. Book a meeting to get commercial claims data for Dr. Kelly and other hematologists and oncologists in California.
Sources: Medicare Physician & Other Practitioners - by Provider and Service (CMS), 2024 data; and Dmand AI Peer Benchmarks
Dr. Karen L. Kelly's patients have a median age of 66
Across all payers, Dmand AI patient panel data puts Dr. Kelly's median patient age at 66, with 80% women.
Dr. Kelly's patients across all payers
Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.
Patient panel by age, all payers
Median age 66
Patient panel by sex, all payers
- Women80%
- Men20%
Source: Dmand AI Patient Panel Data
Dr. Karen L. Kelly wrote 150 Medicare Part D claims in 2022
In 2022, Dr. Kelly wrote 150 Medicare Part D claims. They cover 6 drugs, with $1,071,529 in total drug cost. In 2021, CMS named 348 claims across 9 drugs.
Dr. Kelly's most prescribed drugs by claims, 2022
CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.
Part D claims for drugs CMS names, 2021 to 2022
- 2021
- 2022
- Claims for drugs CMS names
- 2021: 3482022: 15057%
Drugs named by CMS: 6 in 2022, 9 in 2021.
Source: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026
For MedTech and pharma teams
Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.
Dr. Karen L. Kelly has 54 publications on record
Dmand AI links 54 papers to Dr. Kelly, published from 2011 to 2025. 2022 was the busiest year, with 6. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Antineoplastic Combined Chemotherapy Protocols. Dr. Kelly has published most often in Clin Cancer Res. Dr. Kelly's most frequent co-authors are Karen Kelly, MD, David Raymond Gandara, MD and Jonathan Wesley Riess, MD, MS.
Dr. Kelly's papers by year, 2011 to 2025
Topics Dr. Kelly writes about most
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Antineoplastic Combined Chemotherapy Protocols
- Antibodies, Monoclonal, Humanized
- Carcinoma, Squamous Cell
- Protein Kinase Inhibitors
- Docetaxel
- ErbB Receptors
Dr. Kelly's most frequent co-authors
- Karen Kelly, MD31 shared papers
- David Raymond Gandara, MD18 shared papers
- Jonathan Wesley Riess, MD, MS9 shared papers
Recent publications by Dr. Kelly
Eur J Cancer
See who Dr. Kelly researches with
Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. Kelly works with, so you can find a warm path to the right hematologists and oncologists.
Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage
Dr. Karen L. Kelly has worked on 13 clinical trials
Dmand AI links Dr. Kelly to 13 clinical trials, 8 of them phase 1 studies. 1 is still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Mesothelioma. National Cancer Institute (NCI) sponsors the most, 4. Open Payments lists research payments to Dr. Kelly that name 1 trial.
Clinical trials with Dr. Kelly by phase
- 8Phase 1: 8 trials
- 1Phase 1/2: 1 trial
- 3Phase 2: 3 trials
- NonePhase 3: no trials
- NonePhase 4: no trials
Conditions in Dr. Kelly's trials
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Bronchogenic
- Mesothelioma
- Neoplasm Metastasis
- Pancreatic Neoplasms
Investigators on the most trials with Dr. Kelly
- Afshin Dowlati, MD2 shared trials
- Hussein Abdul-Hassan Tawbi, MD2 shared trials
- Olatunji B. Alese, MD1 shared trial
Recent clinical trials with Dr. Kelly
Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer (opens in a new tab)
MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer (opens in a new tab)
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) (opens in a new tab)
Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer (opens in a new tab)
Sources: Dmand AI Research Linkage; and ClinicalTrials.gov (National Library of Medicine)
Dr. Karen L. Kelly received $295,544 in industry payments from 2016 to 2025
CMS Open Payments shows 260 general payments to Dr. Kelly from 23 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 73% of the total. AstraZeneca Pharmaceuticals LP paid the most, $71,783. It also lists 15 research payments totaling $82,800 from 2016 to 2019, naming 1 clinical trial.
General payments to Dr. Kelly by program year, 2016 to 2025
General payments to Dr. Kelly by kind, 2016 to 2025
- Consulting fees$215,77273%
- Travel and lodging$39,12913%
- Speaker and faculty fees$28,58010%
- Food and beverage$5,7112%
- Other$6,3482%
Companies that paid Dr. Kelly the most, 2016 to 2025
Share is of all general payments to this clinician.
Source: Open Payments (CMS), 2025 data, released July 7, 2026
Dr. Karen L. Kelly has 2 awards and honors on record
Dmand AI lists 2 awards for Dr. Kelly, most recently ASCO Fellow in 2012.
Awards and honors for Dr. Kelly
- 2012
- ASCO Fellow
- CMS Stage 1 EHR
Source: Dmand AI Professional Profile Data
Dr. Karen L. Kelly graduated from University of Kansas School of Medicine - Kansas City
Dr. Kelly graduated from University of Kansas School of Medicine - Kansas City in 1984. Dr. Kelly is a member of ASCO.
- Medical school
- Board certified in internal medicine
Source: Dmand AI Professional Profile Data
Dr. Karen L. Kelly accepts plans from 4 insurance carriers
Dr. Kelly is in network with 4 carriers, including Blue Cross Blue Shield of Massachusetts, Blue Cross Blue Shield of Michigan and HCSC. PPO plans come from the most carriers, 3. Check the plan with the practice before a visit.
- Blue Cross Blue Shield of Massachusetts
- Blue Cross Blue Shield of Michigan
- HCSC
- NV State Medicaid
Plan types Dr. Kelly accepts, by number of carriers
- PPO3
- Medicare2
- Medicaid1
- POS1
Source: Dmand AI Insurance Network Data
Sources for Dr. Karen L. Kelly's profile data
| Data on this page | Source |
|---|---|
| NPI, name, sex, specialty and licenses | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data |
| Practice locations and phone | Dmand AI Affiliation Data |
| Primary practice, affiliations and health system | Dmand AI Affiliation DataDmand AI Org Hierarchy Data |
| Medicare services and procedure codes | Medicare Physician & Other Practitioners - by Provider and Service (CMS) (opens in a new tab) |
| State medians for the same specialty | Dmand AI Peer Benchmarks |
| Medicare patients and the all-payer patient panel | Dmand AI Patient Panel Data |
| Part D prescribing | Medicare Part D Prescribers - by Provider and Drug (CMS) (opens in a new tab) |
| Publications, topics and co-authors | PubMed (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage |
| Clinical trials and co-investigators | Dmand AI Research LinkageClinicalTrials.gov (National Library of Medicine) (opens in a new tab) |
| Industry payments | Open Payments (CMS) (opens in a new tab) |
| Awards and committee roles | Dmand AI Professional Profile Data |
| Training, board certification and memberships | Dmand AI Professional Profile Data |
| Insurance carriers and plan types | Dmand AI Insurance Network Data |
| EHR at each practice site | Dmand AI Technology Install Data |
| Similar physicians | Dmand AI Affiliation Data |
Data last refreshed October 2026Report an inaccuracyRemove my information
FAQ
Frequently asked questions about Dr. Karen L. Kelly
Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.
What is Dr. Karen L. Kelly's NPI number?
Dr. Karen L. Kelly's NPI number is 1477651222. It was assigned on September 20, 2006, and it is active in the NPI Registry.
What kind of doctor is Dr. Karen L. Kelly?
Dr. Karen L. Kelly is a hematologist and oncologist in Sacramento, California. The primary specialty in the NPI Registry is Hematology & Oncology Physician (taxonomy code 207RH0003X).
Where does Dr. Karen L. Kelly practice?
Dr. Kelly practices at 2315 Stockton Boulevard, Sacramento, CA 95817. Dr. Kelly's primary practice is UC Davis Medical Center in Sacramento, California, part of University of California Health. Dmand AI also links Dr. Kelly to 1 group practice or clinic.
What is Dr. Karen L. Kelly's office phone number?
The practice phone on file for Dr. Kelly is (916) 734-2011.
What is Dr. Karen L. Kelly's medical license number?
Dr. Kelly's California license number on file is G88845, one of the licenses on file in 4 states.
Which states has Dr. Karen L. Kelly been licensed in?
Dmand AI has state licenses on file for Dr. Kelly in California (2010 to 2024), Kansas, Colorado (1986 to 2007) and New Mexico (1994 to 1997).
Which hospitals is Dr. Karen L. Kelly affiliated with?
Dr. Kelly practices at UC Davis Medical Center in Sacramento, California.
What medical group is Dr. Karen L. Kelly part of?
Dr. Kelly is linked to UC Davis Medical Group.
Does Dr. Karen L. Kelly accept Medicare?
Yes. CMS data shows Dr. Kelly billed Medicare for 13 services in 2022.
Is Dr. Karen L. Kelly board certified?
Yes. Dr. Kelly is board certified in internal medicine by the American Board of Internal Medicine.
Show 8 more questionsShow fewer questions
What services does Dr. Karen L. Kelly bill to Medicare?
In 2022, Dr. Kelly's most billed Medicare services were office visit, established patient (99215).
Where did Dr. Karen L. Kelly go to medical school?
Dr. Kelly graduated from University of Kansas School of Medicine - Kansas City in 1984.
What drugs does Dr. Karen L. Kelly prescribe most?
In 2022 Medicare Part D data, Dr. Kelly's most prescribed drugs by claims were Tagrisso, Dexamethasone and Prochlorperazine Maleate.
Has Dr. Karen L. Kelly received payments from drug or device companies?
CMS Open Payments shows $295,544 in general payments to Dr. Kelly from 23 companies from 2016 to 2025. The largest total came from AstraZeneca Pharmaceuticals LP.
How long has Dr. Karen L. Kelly been practicing?
Dr. Kelly graduated from medical school in 1984, 42 years ago.
Does Dr. Karen L. Kelly do research?
Dmand AI links 54 publications to Dr. Kelly, published from 2011 to 2025. Dr. Kelly has worked on 13 clinical trials.
Who does Dr. Karen L. Kelly publish with?
Dr. Kelly's most frequent co-authors are Karen Kelly, MD (31 shared papers), David Raymond Gandara, MD (18 shared papers) and Jonathan Wesley Riess, MD, MS (9 shared papers).
What insurance does Dr. Karen L. Kelly accept?
Dr. Kelly is in network with 4 carriers, including Blue Cross Blue Shield of Massachusetts, Blue Cross Blue Shield of Michigan and HCSC. PPO plans come from the most carriers, 3. Check the plan with the practice before a visit.
Selling to hematology and oncology practices?
See hematologists and oncologists in California by site of care and group
Find the practices, groups and hospitals they work with, and the right people to contact at each.
- 30 days free
- Self-serve
- No credit card